Editorial
The Puzzle of Aspirin and Sex
N Engl J Med 2005; 352:1366-1368March 31, 2005
- Article
Recently, in New York, the geneticist Luigi Luca Cavalli-Sforza began a brilliant seminar with this introduction: “To understand the present, you have to understand history, and to understand biology, you have to understand evolution, because evolution is the history of biology.” Although Cavalli-Sforza's life of exploration along the branches of the human genetic tree has led him to conclude that there is no genetic basis for race,1 there is most obviously a genetic basis for sex. So powerful is la différence that sexual differentiation probably emerged with the appearance of eukaryotes at least 2 billion years ago, Y emerged from X perhaps 300 million years ago,2 and evolution has maintained the duet assiduously ever since. The biologic speculations to explain this success are many, varied, and wonderful. The biologic differences between women and men are equally so, but in this issue of the Journal, Ridker and colleagues3 describe a difference between the sexes in the cardiovascular response to aspirin that is at once a puzzle and a coda to the recent crescendo of demands that clinical research must always be organized to account for the biologic differences between women and men.
To an approximation, this study, the Women's Health Study, is to women what the earlier Physicians' Health Study, also by the varying group of prolific investigators centered at the Harvard School of Public Health,4 was to men. What they find now in women is the inverse of what they found then in men, and that is the puzzle. The Physicians' Health Study showed that aspirin significantly reduced the risk of myocardial infarction: the reduction was 44 percent in men 50 years of age or older who did not have clinical evidence of coronary disease. There was no significant effect on the risk of stroke and no effect on mortality from cardiovascular causes. The current Women's Health Study shows, at least in women 65 years of age or older who do not have a history of cardiovascular disease, that aspirin has no significant effect either on the risk of myocardial infarction or on the risk of death from cardiovascular causes but that it is associated with a 24 percent reduction in the risk of ischemic stroke and a 17 percent reduction in the risk of stroke overall. Furthermore, the authors strengthen their observations with a meta-analysis comprising an additional 55,580 subjects. The findings in men and women are opposite. How can this be?
Aspirin, or acetylsalicylic acid, was synthesized in the mid-19th century as a product of European chemistry and was perhaps designed to be a less irritating version of salicylic acid.5 The well-known mechanism of aspirin as a permanent inactivator of both forms of cyclooxygenase, the first enzyme in the biosynthetic pathway of prostanoids, is the basis of its prevention of thrombotic vascular events6 and the chemoprevention of cancer. The optimal dose, that which prevents atherothrombosis and minimizes hemorrhage, is unknown; doses as low as 30 mg per day may be effective, and lower doses have not been systematically studied.6 Although there are no reports suggesting that the molecular pharmacology of aspirin differs between the sexes, the pharmacodynamics do differ: concentrations of salicylate are higher in women than in men after identical doses of aspirin, and platelets from women and men who have ingested aspirin show different responses when tested in vitro.7 Aspirin has been shown to be effective in both sexes in many secondary-prevention trials. However, Patrono and colleagues,6 in analyzing this field, have shown that absolute atherothrombotic benefit from aspirin is related to the cardiovascular risk in the population studied, and so a comparison of the control cohorts of the Physicians' Health Study and the Women's Health Study is relevant.
Table 1Table 1
Comparison of Selected Features of the Aspirin Components of the Women's Health Study and the Physicians' Health Study. lists some features of the two studies. The most striking, of course, is the absolute separation of the sexes. Equally salient is the temporal separation, with a span of more than two decades encompassing not only both studies, but also the watershed of our understanding of vascular disease. We cannot know how secular trends during this period contributed to the changed sociobiology of atherosclerosis, but mortality from cardiovascular causes showed an upward trend among women and a downward trend among men.8 Time alone makes the studies not directly comparable. What is quite clear, however, is the difference in the risk of myocardial infarction between the two placebo cohorts: the risk was 97.3 per 100,000 person-years in the current Women's Health Study and 439.7 per 100,000 person-years in the Physicians' Health Study. The Women's Health Study enrolled a healthy and health-conscious group of women, 84.5 percent of whom had a 10-year Framingham risk score of less than 5 percent.3 Conversely, and as the authors point out, the relative risk of stroke is much higher in women than it is in men. Thus, on the basis of Patrono and colleagues' conditional-probability analysis,6 we might understand why the two studies yielded opposite results for myocardial infarction and stroke. But such conjecture would belie the likely biologic basis of these very different results.What are some of the biologic cardiovascular differences between women and men? Whereas slightly more women than men die annually of cardiovascular disease, the age-adjusted incidence of coronary heart disease among white men is about three times that among white women (12.5 vs. 4.0 per 1000 person-years), and among black men it is about twice that among black women (10.6 vs. 5.1 per 1000 person-years).8 Vascular anatomy is also different: women have smaller coronary arteries, and quite remarkably, when a man receives a woman's heart through cardiac transplantation, the smaller female arteries grow larger in the male recipient, independently of body-surface area.9 Similarly, carotid anatomy and the distribution of atherosclerotic plaque are different,10 and histopathologically, plaque has been described as “younger” in women than in men. Vascular reactivity and electrical repolarization of the heart (and its response to drugs) are different, and stress cardiomyopathy is nine times as frequent among women as it is among men.11 Some, but probably not all, of these differences are related to the hormonal milieu. Recently, atheroprotection was linked directly to estrogen,12 with the observation that estrogen up-regulates prostacyclin production by receptor-mediated activation of cyclooxygenase-2 — an observation that may be relevant to the Women's Health Study–Physicians' Health Study conundrum. The cardiovascular systems of women and men are not the same, differing expression of disease follows, and the disquieting results of the current study should not be a complete surprise.
The investigators of the Physicians' Health Study4 and the Women's Health Study3 have produced two landmark studies on the use of aspirin in asymptomatic persons, the results of which segregate according to sex. On the basis of the Women's Health Study,3 for now it would appear reasonable to avoid prescribing “low-dose” aspirin, defined as a daily dose of 75 to 100 mg or so, as a preventative measure for coronary disease in women under the age of 65 years unless the global risk score is very high. But what about the prevention of stroke? Ridker and colleagues conclude, correctly, that the decision to prescribe aspirin for the primary prevention of stroke and other vascular events should be left to the patient and her physician, invoking an ancient truth. Hippocrates, dean of medicine on the island of Cos some 2400 years ago, popularized white-willow salicin, the precursor of aspirin, and wrote in the first of the Aphorisms, “Life is short, the art long, opportunity fleeting, experiment treacherous, judgment difficult.” Life is longer now, but the art is longer still. The aspirin saga needs additional chapters, and clinical research, as the current authors and so many other authorities have concluded, needs always to account for the evolutionary biology of sex.
This editorial was published at www.nejm.org on March 8, 2005.
Source Information
From the Leon H. Charney Division of Cardiology, New York University School of Medicine, New York.
- References
References
1
Cavalli-Sforza LL, Menozzi P, Piazza A. The history and geography of human genes. Princeton, N.J.: Princeton University Press, 1994.
2
Lahn BT ,Page DC . Four evolutionary strata on the human X chromosome. Science 1999;286:964-967[Erratum, Science 1999;286:2273.]
CrossRef | Web of Science | Medline3
Ridker PM ,Cook NR ,Lee I-M , et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 2005;352:1293-1304
Full Text | Web of Science | Medline4
Steering Committee of the Physicians' Health Study Research Group
Full Text | Web of Science | Medline5
Levin RI . Theriac found? Nitric oxide-aspirin and the search for the universal cure. J Am Coll Cardiol 2004;44:642-643
CrossRef | Web of Science | Medline6
Patrono C ,Coller B ,Dalen JE , et al. Platelet-active drugs: the relationships among dose, effectiveness, and side effects. Chest 2004;119:Suppl:39S-63S
CrossRef | Web of Science7
Levin RI ,Harpel PC ,Weil D ,Chang TS ,Rifkin DB . Aspirin inhibits vascular plasminogen activator in vivo: studies utilizing a new assay to quantify plasminogen activator activity. J Clin Invest 1984;74:571-580
CrossRef | Web of Science | Medline8
Heart disease and stroke statistics — 2005 update. Dallas: American Heart Association, 2005.
9
Herity NA ,Lo S ,Lee DP , et al. Effect of a change in gender on coronary arterial size: a longitudinal intravascular ultrasound study in transplanted hearts. J Am Coll Cardiol 2003;41:1539-1546
CrossRef | Web of Science | Medline10
Schulz UGR ,Rothwell PM . Sex differences in carotid bifurcation anatomy and the distribution of atherosclerotic plaque. Stroke 2001;32:1525-1531
CrossRef | Web of Science | Medline11
Wittstein IS ,Thiemann DR ,Lima JAC , et al. Neurohumoral features of myocardial stunning due to sudden emotional stress. N Engl J Med 2005;352:539-548
Full Text | Web of Science | Medline12
Egan KM ,Lawson JA ,Fries S , et al. COX-2-derived prostacyclin confers atheroprotection on female mice. Science 2004;306:1954-1957
CrossRef | Web of Science | Medline
- Citing Articles (27)
Citing Articles
1
Paul A. Gurbel, Udaya S. Tantry. 2011. Resistance to Antiplatelet Therapy. .
CrossRef2
Christine Cole Johnson, Richard B Hayes, Robert E Schoen, Marc J Gunter, Wen-Yi Huang. (2010) Non-Steroidal Anti-Inflammatory Drug Use and Colorectal Polyps in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. The American Journal of Gastroenterology 105:12, 2646-2655
CrossRef3
Shahzya S Huda, Dilys J Freeman, Scott M Nelson. (2009) Short- and long-term strategies for the management of hypertensive disorders of pregnancy. Expert Review of Cardiovascular Therapy 7:12, 1581-1594
CrossRef4
Jeffrey S. Berger, Deepak L. Bhatt, Christopher P. Cannon, Zhengming Chen, Lixin Jiang, James B. Jones, Shamir R. Mehta, Marc S. Sabatine, Steven R. Steinhubl, Eric J. Topol, Peter B. Berger. (2009) The Relative Efficacy and Safety of Clopidogrel in Women and Men. Journal of the American College of Cardiology 54:21, 1935-1945
CrossRef5
Arjen Joosse, Elsje R Koomen, Mariël K Casparie, Ron M C Herings, Henk-Jan Guchelaar, Tamar Nijsten. (2009) Non-Steroidal Anti-Inflammatory Drugs and Melanoma Risk: Large Dutch Population-Based Case–Control Study. Journal of Investigative Dermatology 129:11, 2620-2627
CrossRef6
Udaya S. Tantry, Elisabeth Mahla, Paul A. Gurbel. (2009) Aspirin Resistance. Progress in Cardiovascular Diseases 52:2, 141-152
CrossRef7
S. Shakib. (2009) Aspirin for primary prevention: do potential benefits outweigh the risks?. Internal Medicine Journal 39:6, 401-407
CrossRef8
G. Telman, E. Kouperberg, E. Sprecher, D. Yarnitsky. (2009) Pretreatment with aspirin and etiology of first-ever ischemic stroke in young and middle-aged patients. Journal of the Neurological Sciences 281:1-2, 2-5
CrossRef9
Robina Matyal. (2008) Newly Appreciated Pathophysiology of Ischemic Heart Disease in Women Mandates Changes in Perioperative Management: A Core Review. Anesthesia & Analgesia 107:1, 37-50
CrossRef10
Robina Matyal, Feroze Mahmood, Peter Panzica, Frank Pomposelli, Kyung W. Park, Allen Hamden, Mark Schermerhorn, Philip Hess. (2008) Sex-Related Differences in Outcome After High-Risk Vascular Surgery After the Administration of β-Adrenergic–Blocking Drugs. Journal of Cardiothoracic and Vascular Anesthesia 22:3, 354-360
CrossRef11
Charles H Hennekens, Wendy R Schneider. (2008) The need for wider and appropriate utilization of aspirin and statins in the treatment and prevention of cardiovascular disease. Expert Review of Cardiovascular Therapy 6:1, 95-107
CrossRef12
Charles H. Hennekens. (2007) Aspirin in the treatment and prevention of cardiovascular disease: Current perspectives and future directions. Current Atherosclerosis Reports 9:5, 409-416
CrossRef13
Margaret May, Debbie A. Lawlor, Rita Patel, Ann Rumley, Gordon Lowe, Shah Ebrahim. (2007) Associations of von Willebrand factor, fibrin D-dimer and tissue plasminogen activator with incident coronary heart disease: British Womenʼs Heart and Health cohort study. European Journal of Cardiovascular Prevention & Rehabilitation 14:5, 638-645
CrossRef14
Erhard Haus. (2007) Chronobiology of hemostasis and inferences for the chronotherapy of coagulation disorders and thrombosis prevention. Advanced Drug Delivery Reviews 59:9-10, 966-984
CrossRef15
J.A. González-Correa, M.M. Arrebola, J. Muñoz-Marín, A. Moreno, A. Guerrero, I. Arranz, F. Sánchez De La Cuesta, J.P. De La Cruz. (2007) Gender differences in the effect of aspirin on retinal ischemia, prostanoid synthesis and nitric oxide production in experimental type 1-like diabetes. Vascular Pharmacology 47:2-3, 83-89
CrossRef16
PAUL A. GURBEL, UDAYA S. TANTRY. (2006) Aspirin and Clopidogrel Resistance: Consideration and Management. Journal of Interventional Cardiology 19:5, 439-448
CrossRef17
N. M. Schmitt, W. Kirch. (2006) Besonderheiten der Pharmakotherapie bei Frauen im Alter. Der Gynäkologe 39:5, 367-372
CrossRef18
Udaya S Tantry, Amena Etherington, Kevin P Bliden, Paul A Gurbel. (2006) Antiplatelet therapy: current strategies and future trends. Future Cardiology 2:3, 343-366
CrossRef19
B.J. Gersh. (2006) A Randomized Trial of Low-Dose Aspirin in the Primary Prevention of Cardiovascular Disease in Women. Yearbook of Cardiology 2006, 270-272
CrossRef20
Charles H Hennekens, Danielle Hollar, Colin Baigent. (2006) Sex-related differences in response to aspirin in cardiovascular disease: an untested hypothesis. Nature Clinical Practice Cardiovascular Medicine 3:1, 4-5
CrossRef21
Patrono, Carlo, García Rodríguez, Luis A., Landolfi, Raffaele, Baigent, Colin, . (2005) Low-Dose Aspirin for the Prevention of Atherothrombosis. New England Journal of Medicine 353:22, 2373-2383
Full Text22
Cheryl D Bushnell. (2005) Oestrogen and stroke in women: assessment of risk. The Lancet Neurology 4:11, 743-751
CrossRef23
I U Ali, B T Luke, M Dean, P Greenwald. (2005) Allellic variants in regulatory regions of cyclooxygenase-2: association with advanced colorectal adenoma. British Journal of Cancer 93:8, 953-959
CrossRef24
Freek WA Verheugt, Sidney C Smith. (2005) The lady aspirin for cardiovascular disease. The Lancet 366:9492, 1148-1150
CrossRef25
(2005) Primärprävention kardiovaskulärer Erkrankungen bei Frauen. Der Internist 46:9, 1043-1046
CrossRef26
Bruce B. Lerman, Richard B. Devereux, Peter M. Okin. (2005) An Introduction. Journal of the American College of Cardiology 45:11, B2-B3
CrossRef27
H. R. Vries. (2005) ASA ter voorkoming van een hartinfarct werkt niet bij vrouwen. Medisch-Farmaceutische Mededelingen 43:6, 164-165
CrossRef
